THE POTENTIAL HEALING OF CANCER WITH P53 (RE)ACTIVATORS

En savoir plus sur le livre

The book presents a groundbreaking strategy for complete cancer treatment through two novel drug compounds, PT162 and PT167, developed by Andreas J. Kesel. These drugs target the Warburg effect, exploiting cancer's reliance on glycolysis due to mitochondrial dysfunction. Both compounds demonstrate significant efficacy in vitro against 60 cancer cell lines, inducing apoptosis by reactivating p53 and disrupting cyclin D1 regulation. The book details the chemistry behind these compounds and their apoptotic mechanisms, offering hope for innovative cancer therapies.